Table 2.
Pain measures in AIM compared with other neuromuscular or rheumatic diseases
| Study | AIM subsets | Pain severity* | Findings | |
| AIM | Disease comparators | |||
| SF-36 BP (additive 0–100, norm-based mean 50, SD 10); lower score, more pain | ||||
| Sadjadi et al29 | IBM | Mean±SD 69±27 |
Mean±SD FSHD: 67±24 MyoDys: 75±25 CMT 1: 69±26 Various NMDs: 63±26 |
Comparable burden of pain with IBM and other NMDs |
| Goreshi et al23 | DM | Norm-based Mean: 50 |
Norm-based Mean: SLE: 43 CLE: 54 |
|
| Feldon et al22 | DM, PM, IBM, adult JDM | Norm-based Mean±SE 43±0.28 |
Norm-based Mean±SE RA: 42±0.85 |
Comparable burden of pain with RA |
| NHP score (0–100); higher score, more pain | ||||
| Chung et al19 | DM, PM | Mean±SD 30±32 |
Mean±SD RA: 49±34 OP: 33±36 OA: 41±27 |
Less pain in AIM compared with RA and OA (p<0.002) |
| INQOL score; higher score, more pain | ||||
| Rose et al33 | DM, PM, IBM | Mean±SD PM/DM: 70±20 IBM: 46±29 |
Mean±SD LGMD: 45±26 FSHD: 40±23 MyoDys: 41±27 Various NMDs: 35±23 |
More pain in DM/PM compared with NMD |
*If not shown, measure of dispersion not provided.
AIM, autoimmune idiopathic myopathy; SF-36 BP, 36-Item Short Form Bodily Pain; CLE, cutaneous lupus erythematosus; CMT 1, Charcot-Marie-Tooth type 1; DM, dermatomyositis; FSHD, facioscapulohumeral dystrophy; IBM, inclusion body myositis; INQOL, Individualised Neuromuscular Quality of Life Questionnaire; JDM, juvenile dermatomyositis; LGMD, limb–girdle muscular dystrophy; MyoDys, myotonic dystrophy; NHP, Nottingham Health Profile; NMD, neuromuscular disease; OA, osteoarthritis; OP, osteoporosis; PM, polymyositis; RA, rheumatoid arthritis; SLE, sytemic lupus erythematosus.